Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Bioventures 2014 L.P. Mpm Sells 94,063 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $1.29, for a total value of $121,341.27. Following the completion of the sale, the insider directly owned 6,147,610 shares of the company’s stock, valued at approximately $7,930,416.90. This trade represents a 1.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Friday, October 31st, Bioventures 2014 L.P. Mpm sold 114,044 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total value of $145,976.32.
• On Thursday, October 30th, Bioventures 2014 L.P. Mpm sold 86,936 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total value of $124,318.48.
• On Wednesday, October 29th, Bioventures 2014 L.P. Mpm sold 134,240 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total value of $208,072.00.
• On Tuesday, October 28th, Bioventures 2014 L.P. Mpm sold 69,068 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total value of $113,271.52.
• On Monday, October 27th, Bioventures 2014 L.P. Mpm sold 72,709 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total value of $125,059.48.

Werewolf Therapeutics Stock Performance

Shares of HOWL opened at $1.31 on Tuesday. The business has a 50-day moving average of $1.62 and a 200 day moving average of $1.32. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.60 and a fifty-two week high of $2.52. The firm has a market cap of $59.91 million, a P/E ratio of -0.80 and a beta of 0.73. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.30 and a current ratio of 5.30.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.10. As a group, research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on HOWL shares. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Citigroup restated a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Bank of America cut their target price on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 25th. Finally, JMP Securities cut their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Institutional Trading of Werewolf Therapeutics

A number of large investors have recently modified their holdings of the business. MPM Bioimpact LLC boosted its position in shares of Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after acquiring an additional 20,799 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after acquiring an additional 23,852 shares during the last quarter. MPM Asset Management LLC boosted its position in shares of Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after acquiring an additional 25,688 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Werewolf Therapeutics during the 2nd quarter valued at about $28,000. Finally, Bank of America Corp DE boosted its position in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares during the last quarter. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.